Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Reported positive topline data from the pivotal Phase 3 REST-ON studyStrengthened balance sheet with $190 million in gross proceeds from a private placement in February 2020 and public equity offering...
-
DUBLIN, Ireland, May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for...
-
DUBLIN, Ireland, April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
DUBLIN, Ireland, April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p<0.001), and clinically meaningful improvement across all three co-primary...
-
DUBLIN, Ireland, March 25, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2020Raised $65 million in gross proceeds from private placement with leading biotech investment funds...
-
DUBLIN, Ireland, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
DUBLIN, Ireland, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
-
- - -A total of 212 patients enrolled in the REST-ON study exceeds the trial’s enrollment target of 205- - -Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Dec. 17, 2019 ...